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Carcinoma of the mobile tongue can be successfully treated by surgery or
radiotherapy provided that the tumor is small, typically with a thickness less than
or equal to 1.2 cm.
1 We have been using the Manchester System for the past 3
decades, although sometimes external radiation was also combined with cesium
(Cs) brachytherapy. Hosokawa, et al.
2 has reported on the treatment results of
combination therapy at our institute. The percent of patients with 5 year local
control for T1 and T2 diseases were 92.6% and 62.7%, respectively.
2 The value
for T1 disease was comparable with the results achieved at other institutions.
However, the T2 control rate was far from satisfactory, and therefore, in 1993, we
changed the treatment protocol from combination therapy to brachytherapy alone
(7000 cGy). Since then, the 3 year local control rates obtained for T2 disease was
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Purpose: Deciding on treatment carcinoma of the tongue when the tumor has a
thickness of 1.5 cm or more is difficult. Surgery often requires wide resection and
re-construction, leading to considerable functional impairment. A cesium implant
is an attractive option, but according to the Manchester System, a two plane
implant is needed. Materials and Methods: According to the textbook, a tumor is
sandwiched between the needles, which are implanted at the edge of the tumor.
This may cause an unnecessarily high dose to the outer surface of the tongue,
which sometimes leads to a persistent ulcer. To avoid this complication, we invented
a modified implantation method, and applied the method to five consecutive
patients. Results: With a minimum follow-up of 2 years, all primary tumors in 5
consecutive patients have been controlled. No complications occurred in soft tissue
of the tongue or in the mandible. Conclusion: Our modified Manchester System
was feasible and effective for tumors that has a thickness of 1.5 cm or more. 
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88% (unpublished data). Compared to T1 disease, T2
disease covers a wide range of diseases; the horizontal and
vertical lengths vary from 2 to 4 cm, and thickness is
sometimes ambiguous. Among these characteristics, tumor
thickness is the major concern when treatment policy is
discussed at the head-and-neck tumor board, which
consists of head-and-neck surgeons, oral surgeons, den-
tists, interventional radiologists, and radiation oncologists.
The tumor board has met weekly since the 1970s. Every
new patient with head-and-neck cancer has been examined
at the same institution by doctors with different expertise.
After discussion, possible treatment options are presented
to patients and they choose their preferred treatment. When
tumor thickness approaches 1.5 cm, our treatment options
can vary considerably. From the perspective of a radiation
oncologists, a two plane implant is required,
1 although
there is the high risk of necrosis of the mucosa and man-
dible. The University of Florida group reported that the
incidence of severe complications were 9%.
3 Surgeons
hesitate in recommending a near hemiglossectomy parti-
cularly for young patients. This is because the procedures
are to some extent associated with orocutaneous fistula,
flap necrosis, dysphagia, and speech disturbance.
2 Hence,
treatments for tumors such as ours are controversial. In this
short report, we discuss the difficulties regarding manage-
ment of thick cancer of the tongue. 
From August 2003 to February 2005, 5 patients with
tumor thickness close to 1.5 cm were referred to our tumor
board. Tumor thickness was evaluated manually and by
magnetic resonance imaging. The well known Manchester
System specifies using a single plane implantation only for
tumors with a thickness of less than 12 mm. If the thickness
exceeds 12 mm, a two plane implantation should be im-
plemented. Fig. 1 shows the concept of a two plane implant.
As shown, full strength Cs needles are implanted at the
outer edge of the tongue. It is likely that the risk of mucosal
necrosis will be high. We therefore modified this implant
system. According to this modification, the mucosal sur-
face will still receive 7,000 cGy, but within the tumor there
will be 1.1-1.2 times higher dose points. Fig. 2 is a repre-
sentation of our modified implant. This is an ideal implan-
tation. In reality, the outer needles were inserted up to a
depth of 2-3 mm from the mucosal surface. To reduce the
dose to the mandible, we used a custom-made spacer for
each patient as described previously.
4 Cs implantation was
carried out by T.N., and it was performed under general
anesthesia in all cases. The needles’ position was observed
by a portable diagnostic X-ray machine, and if needed, re-
insertion of a needle was performed. A nasopharyngeal
airway was kept in place for a few days to prevent possible
air way obstruction due to edema. Patients were examined
using computed tomography (CT) to confirm good 3-di-
mentional needle alignment. The image was also used to
measure the horizontal length of the needles for dose
calculation. In both planes, the needles were inserted
according to the Manchester System. The dose was
prescribed at the plane 0.5 cm away from the source plane
(coincidentally, this value meant that the prescribed dose
was on the mucosal surface, as the tumor thickness was
about 1.5 cm in all patients). The dose rate at the mucosal
surface varied from 1,211 cGy/day to 1,410 cG/day with a
mean dose of 1,262 cGy/day. The mean dose of the inner
MATERIALS AND METHODS
Fig. 1. Original Manchester System for T2N0 with a thickness of 1.5 cm. The
tumor is shown sandwiched between full length needles. Dose is prescribed at
the 0.5 cm plane B from the lateral border of the tongue. Overdose is a concern
at plane A.
Fig. 2. Modified Manchester System at Hokkaido University. Insert full intensity
needles 5 mm from the lateral border of the tongue. Half intensity needles were
implanted at the medial border of the tumor. Dose is prescribed at plane A. Dose
at plane D, which is 1.1 - 1.2 time higher than that at the plane A, is a concern.A Modified Manchester System Cs Implant 
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plane was 1,469 cG/day with a range from 1,392 cGy/day
to 1,499 cGy/day. In one patient, a needle implanted near
the base of the tongue was difficult to remove, and the
needle was removed under general anesthesia.
Table 1 shows the characteristics and outcomes of the
patients. It also includes the time to be spent for insertion.
One patient died from metastasis to the lung, and another
patient died from metastasis to the lymphnodes. The for-
mer patient (Pt. 3) needed 2.5 hours for insertion (i.e.,
reinsertion was necessary to obtain an ideal configuration
of needles). The patient with lymph node metastasis (Pt. 1)
refused selective neck dissection because for cosmetic
reasons, and developed repeated nodal metastases. Node
removal was performed whenever metastasis developed.
In all the patients who developed nodal recurrences, their
primaries were preserved. Acute mucositis (RTOG Grade
3) subsided within one month after removal of needles in
all patients and there have been no mucosal bleedings. At 6
months, all patients developed atrophy (RTOG Grade 2) of
the tongue. However this did not cause any inconvenience
to the patients.
Fig. 3 shows a typical case with a 1.5 cm-thick T2 tumor.
The oral surgeons’ recommendation was a near- hemi-
glossectomy. In addition, they believed that even if brachy-
therapy succeeded, because of the risk of nodal relapse the
primary and the nodal area should be removed en bloc.
This is because they think that if a primary recurs after a
neck dissection, it will be almost impossible to salvage the
patient. The head-and-neck surgeons had an intermediate
opinion. They thought that the tumor was curable with
either an operation or brachytherapy, although surgery
would provide higher local control. Because of the pati-
ent’s age, and the resulting undesirable cosmetic effect,
disturbance in speech, swallowing, and taste, secondary to
surgical intervention, brachytherapy was recommended.
Radiation oncologists were a little hesitant in performing
brachytherapy because of the high complication rate; how-
ever, the patient decided to be treated with brachytherapy.
To minimize complications, we performed Cs implantation
with the modified Manchester System mentioned above.
At 2.5 years after the treatment, the patient has had no
signs of complications or loco-regional recurrence.
It is well known that for carcinoma of the tongue, tumor
thickness is one of the prognostic factors of regional nodal
recurrence.
5,6 Our nodal recurrence rate was 60% (3/5),
which is consistent with those reports. It should be noted
that there has been no nodal recurrence among the 3 pati-
ents treated with selective neck dissection. There have been
no reports on the relationship between Cs insertion time
and outcome, but there might have been tumor cell seeding
during the prolonged procedure (Pt. 3). Selective neck dis-
section has gradually gained popularity, and several studies
have reported its efficacy.
7-10 It is unlikely that our patients
will develop further recurrence in the neck, as around 90%
of lymphnode relapse occurs within 1 year of the first
event.
12 There has been controversy regarding how to ma-
nage a clinically controlled tongue in a patient who develops
nodal disease. In our institute, although there is no defini-
tive policy, a large primary that was initially thought to be
uncontrollable by brachytherapy is a candidate for neck
dissection with near-hemiglossectomy. The Kyushu Uni-
versity Group analyzed 396 patients who were treated with
RESULTS
DISCUSSION
Table 1.Patient Characteristics and Treatment Outcome
Follow-up Maximum
Time to  Complication
Present
No.Yrs
(months)
Pathology Thickness
distance
Local spend for (RTOG Grade) Neck node
status
Cs insertion Early Lete
17 0 3 6
Poorly diff. 
1.7 cm 3.2 cm NED 1.5 hrs GIII GII
7 months-ND died of 
SCC (level I only) disease
25 7 3 8
Moderately
1.6 cm 3.5 cm NED 2 hrs GIII GII
5 months-ND
NED 
diff. SCC (level II and III)
32 9 2 4
Poorly diff. 
1.5 cm 3.5 cm NED 2.5 hrs GIII GII
6 months-ND died of lung 
SCC (level I and III) metastasis
43 0 3 0
Well diff.
1.5 cm 3.0 cm NED 1.5 hrs GIII GII None NED
SCC
55 3 2 7
Well diff.
1.6 cm 2.9 cm NED 1 hr GIII GII None NED
SCC
ND, neck dissection; NED, no evidence of disease.Takeshi Nishioka, et al.
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brachytherapy and concluded that glossectomy is unneces-
sary if primary sites were clinically controlled.
11 However,
the number of cases with nodal dissection with glossec-
tomy was only 6 and their T stage was not documented. 
In the present study, we used magnetic resonance imag-
ing (MRI) to measure tumor thickness. The tumor border
was clearly seen in all cases. This is very helpful in making
a treatment decision and also for simulating Cs implanta-
tion. The inner tumor border is sometimes ambiguous. Our
current diagnostic procedures include MRI, CT, and posi-
tron emission tomography (PET). The high local control
rate in this study might have been achieved because of the
careful treatment planning based on these images. As to
the local control rate, Hareyama, et al.
13 reported treatment
results of 130 patients treated with brachytherapy. Their
local control rate for T3 cases was 70.9%.
13 Since our cases
were nearly T3 in terms of tumor thickness, in the sense
that they needed two-plane implantation, our treatment
results are comparable with theirs. The aforementioned
study indicates that the overall incidence of ulceration of
the tongue and mandibular complication was 20% (26/130)
and 13% (17/130), respectively.
13 Although the follow-up
period is still short, our patients did not show any signs of
complications in soft tissues and mandibles. We would
like to believe that this was due to our modified method of
insertion. A multidiscipline approach is also important in
deciding on a treatment plan. Previously, we reported a T4
tongue cancer that was treated with intra-arterial chemo-
therapy and brachytherapy using high-dose-rate (HDR)
iridium.
14 The patient continues to be free from diseases
and complications 7 years after treatment. To the best of
our knowledge, patients being evaluated at the same time
by physicians with different expertise, followed by a
discussion on the best treatment plan, are rare in Japan and
abroad. In many institutions, patients are simply “referred”
to the radiation oncology department. The multidisciplinary
approach is an established tradition in our university and it
is what we want to continue in the future.
Dose heterogeneity occurs with the modified Man-
chester System; in other words, the outer surface receives
7,000 cGy but the inner 0.5-cm plane may receive 8,000
cGy. We initially thought that a few patients would develop
a persistent mucosal ulcer. However, to our surprise, no pati-
ents developed any signs of a mucosal ulcer. This could
indicate that the presence of the high dose area in deep
muscle (far from the mucosa surface) does not lead to a mu-
Fig. 3. (A) Gadolinium-enhanced MR image clearly revealed the tumor. The thickness was 15.3 mm and the height was 27.5 mm. (B) Operating
room X-ray image. A total of 15 Cs needles were implanted. Their alignment was satisfactory. (C) CT image immediately after implant. The lateral
needles were implanted 0.5 cm from the mucosal surface. The inner needles were placed 1.0 cm from the lateral needles. This alignment was the
same as in the simulation. The dose prescription plane is highlighted in yellow (1,198 rad/day) and the inner plane 5 mm away from the outer
needle plane is highlighted in red (1,437 rad/day). The dose at the red plane will end up with 20% higher than that of the lateral portion of the tongue.
(D) Appearance of the tongue mucosa 2.5 years after the implant. The mucosa appears slightly white, there is no sign of tissue necrosis. (E) Slight
atrophy is seen in the area of the implant. When the tongue protrudes, a slight deviation to the left is observed. 
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cosal ulcer. The T4 case mentioned above also received 30
Gy external radiation and 48 Gy in 12 HDR fractions, and
did not develop any signs of a mucosal ulcer. Although the
number of cases is too small to discover the reason, good
needle arrangement may be a factor in both local control
and the absence of complications. For the past 15 years,
most brachytherapy, including all 5 cases in the present
report, were performed by T.N. After a discussion between
the authors, H.S, and M.N. regarding the reason for the
low primary control rates in T2 cancer, M.N. suggested
that external radiation should be omitted, and in 1993 we
changed the treatment policy to 7,000 cGy using Cs impl-
ants only. A learning curve may have also contributed to
the good local control in the present series. This is not based
on science, but the success of brachytherapy seems to de-
pend on a physician’s enthusiasm. Cs implants for tongue
cancer are no longer available at a hospital in Manchester
since the specialist for this treatment modality retired (per-
sonal communication).
In summary, although the number of patients in this
series was small, the modified Manchester System resulted
in good local control and no complications. Evaluation of
tumor geometry by advanced diagnostic tools is important
for treatment planning, and good needle alignment is
essential. Increasing the number of patients treated by this
technique is required to make a definitive conclusion.
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